Antihypertensive drug explained

Antihypertensives are a class of drugs that are used to treat hypertension (high blood pressure). Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%, and can reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.[1] There are many classes of antihypertensives, which lower blood pressure by different means. Among the most important and most widely used medications are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers.

Which type of medication to use initially for hypertension has been the subject of several large studies and resulting national guidelines. The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered.[2] The several classes of antihypertensives differ in side effect profiles, ability to prevent endpoints, and cost. The choice of more expensive agents, where cheaper ones would be equally effective, may have negative impacts on national healthcare budgets.[3] As of 2018, the best available evidence favors low-dose thiazide diuretics as the first-line treatment of choice for high blood pressure when drugs are necessary.[4] Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (from both efficacy and cost points of view), an ACE inhibitor is recommended by NICE in the UK for those under 55 years old.[5]

Diuretics

Diuretics help the kidneys eliminate excess salt and water from the body's tissues and blood.

In the United States, the JNC8 (Eighth Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommends thiazide-type diuretics to be one of the first-line drug treatments for hypertension, either as monotherapy or in combination with calcium channel blockers, ACE inhibitors, or angiotensin II receptor antagonists. There are fixed-dose combination drugs, such as ACE inhibitor and thiazide combinations. Despite thiazides being cheap and effective, they are not prescribed as often as some newer drugs. This is because they have been associated with increased risk of new-onset diabetes and as such are recommended for use in patients over 65, for whom the risk of new-onset diabetes is outweighed by the benefits of controlling systolic blood pressure.[6] Another theory is that they are off-patent and thus rarely promoted by the drug industry.[7]

Medications that are classified as potassium-sparing diuretics which block the epithelial sodium channel (ENaC), such as amiloride and triamterene, are seldom prescribed as monotherapy. ENaC blocker medications need stronger public evidence for their blood pressure reducing effect.[8]

Calcium channel blockers

Calcium channel blockers block the entry of calcium into muscle cells in artery walls, resulting in the relaxation of muscle cells and vasodilation.[9] [10]

The 8th Joint National Committee (JNC-8) recommends calcium channel blockers to be a first-line treatment either as monotherapy or in combination with thiazide-type diuretics, ACE inhibitors, or angiotensin II receptor antagonists for all patients regardless of age or race.[11]

The ratio of CCBs' anti-proteinuria effect, non-dihydropyridine to dihydropyridine was 30 to −2.[12] The anti-proteinuria effect of non-dihydropyridine is due to better selectivity during glomerular filtration and/or a lower perfusion rate through the renal system.

Notable side effects of CCBs include edema, flushing in the face, headache, drowsiness, and dizziness.

ACE inhibitors

ACE inhibitors inhibit the activity of angiotensin-converting enzyme (ACE), an enzyme responsible for the conversion of angiotensin I into angiotensin II, a potent vasoconstrictor.[13]

A systematic review of 63 trials with over 35,000 participants indicated ACE inhibitors significantly reduced doubling of serum creatinine levels compared to other drugs (ARBs, α blockers, β blockers, etc.), and the authors suggested this as a first line of defense. The AASK trial showed that ACE inhibitors are more effective at slowing down the decline of kidney function compared to calcium channel blockers and beta blockers.[14] As such, ACE inhibitors should be the drug treatment of choice for patients with chronic kidney disease regardless of race or diabetic status.

However, ACE inhibitors (and angiotensin II receptor antagonists) should not be a first-line treatment for black hypertensives without chronic kidney disease. Results from the ALLHAT trial showed that thiazide-type diuretics and calcium channel blockers were both more effective as monotherapy in improving cardiovascular outcomes compared to ACE inhibitors for this subgroup. Furthermore, ACE inhibitors were less effective in reducing blood pressure and had a 51% higher risk of stroke in black hypertensives when used as initial therapy compared to a calcium channel blocker.[15] There are fixed-dose combination drugs, such as ACE inhibitor and thiazide combinations.[16]

Notable side effects of ACE inhibitors include dry cough, high blood levels of potassium, fatigue, dizziness, headaches, loss of taste and a risk for angioedema.[17]

Angiotensin II receptor antagonists

Angiotensin II receptor antagonists work by antagonizing the activation of angiotensin receptors.[18]

In 2004, an article in the BMJ examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of myocardial infarction (heart attack).[19] The matter was debated in 2006 in the medical journal of the American Heart Association. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.[20] [21]

In the VALUE trial, the angiotensin II receptor blocker valsartan produced a statistically significant 19% (p=0.02) relative increase in the prespecified secondary end point of myocardial infarction (fatal and non-fatal) compared with amlodipine.[22]

The CHARM-alternative trial showed a significant +52% (p=0.025) increase in myocardial infarction with candesartan (versus placebo) despite a reduction in blood pressure.[23]

As a consequence of AT1 blockade, ARBs increase angiotensin II levels several-fold above baseline by uncoupling a negative-feedback loop. Increased levels of circulating Angiotensin II result in unopposed stimulation of the AT2 receptors, which are, in addition upregulated. Recent data suggest that AT2 receptor stimulation may be less beneficial than previously proposed and may even be harmful under certain circumstances through mediation of growth promotion, fibrosis, and hypertrophy, as well as proatherogenic and proinflammatory effects.[24] [25] [26]

ARBs happens to be the favorable alternative to ACE inhibitors if the hypertensive patients with the heart failure type of reduced ejection fraction treated with ACEis was intolerant of cough, angioedema other than hyperkalemia or chronic kidney disease.[27] [28] [29]

Adrenergic receptor antagonists

Beta-blockers can block beta-1 adrenergic receptors and/or beta-2 adrenergic receptors. Those that block beta-1-adrenergic receptors prevent the binding of endogenous catecholamines (such as epinephrine and norepinephrine), which ultimately reduces blood pressure through decreasing renin and cardiac output release. Those that block beta-2-adrenergic receptors reduce blood pressure through increased relaxation of smooth muscle.

Alpha-blockers can block alpha-1 adrenergic receptors and/or alpha-2 adrenergic receptors.[30] Those that block alpha-1-adrenergic receptors on vascular smooth muscle cells prevent vasoconstriction. Blockade of alpha-2-adrenergic receptors prevents the negative feedback mechanism of norepinephrine (NE). Non-selective alpha-blockers generate a balance whereby alpha-2-blockers release NE to reduce the vasodilation effects induced by alpha-1-blockers.

Although beta blockers lower blood pressure, they do not have a positive benefit on endpoints as some other antihypertensives do.[31] In particular, beta-blockers are no longer recommended as first-line treatment due to relative adverse risk of stroke and new-onset of type 2 diabetes when compared to other medications, while certain specific beta-blockers such as atenolol appear to be less useful in overall treatment of hypertension than several other agents.[32] A systematic review of 63 trials with over 35,000 participants indicated β-blockers increased the risk of mortality, compared to other antihypertensive therapies.[33] They do, however, have an important role in the prevention of heart attacks in people who have already had a heart attack.[34] In the United Kingdom, the June 2006 "Hypertension: Management of Hypertension in Adults in Primary Care"[35] guideline of the National Institute for Health and Clinical Excellence, downgraded the role of beta-blockers due to their risk of provoking type 2 diabetes.[36]

Despite lowering blood pressure, alpha blockers have significantly poorer endpoint outcomes than other antihypertensives, and are no longer recommended as a first-line choice in the treatment of hypertension.[37] However, they may be useful for some men with symptoms of prostate disease.

Vasodilators

Vasodilators act directly on the smooth muscle of arteries to relax their walls so blood can move more easily through them; they are only used in hypertensive emergencies or when other drugs have failed, and even so are rarely given alone.[38]

Sodium nitroprusside, a very potent, short-acting vasodilator, is most commonly used for the quick, temporary reduction of blood pressure in emergencies (such as malignant hypertension or aortic dissection).[39] [40] Hydralazine and its derivatives are also used in the treatment of severe hypertension, although they should be avoided in emergencies.[40] They are no longer indicated as first-line therapy for high blood pressure due to side effects and safety concerns, but hydralazine remains a drug of choice in gestational hypertension.[39]

Renin inhibitors

Renin comes one level higher than angiotensin converting enzyme (ACE) in the renin–angiotensin system. Renin inhibitors can therefore effectively reduce hypertension. Aliskiren (developed by Novartis) is a renin inhibitor which has been approved by the U.S. FDA for the treatment of hypertension.[41]

Aldosterone receptor antagonist

Aldosterone receptor antagonists, also known as mineralocorticoid receptor antagonist (MRA) can lower blood pressure by blocking the binding of aldosterone to the mineralocorticoid receptor. Spironolactone and eplerenone are MRAs that causes a block in the reabsorption of sodium, resulting in a decrease in blood pressure.[42] [43]

Aldosterone receptor antagonists are not recommended as first-line agents for blood pressure,[44] but spironolactone and eplerenone are both used in the treatment of heart failure and resistant hypertension.

Alpha-2 adrenergic receptor agonists

Central alpha agonists lower blood pressure by stimulating alpha-receptors in the brain which open peripheral arteries easing blood flow. These alpha 2 receptors are known as autoreceptors which provide negative feedback in neurotransmission (in this case, the vasoconstriction effects of adrenaline).Central alpha agonists, such as clonidine, are usually prescribed when all other anti-hypertensive medications have failed. For treating hypertension, these drugs are usually administered in combination with a diuretic.

Adverse effects of this class of drugs include sedation, drying of the nasal mucosa and rebound hypertension upon discontinuation.[45]

Some indirect anti-adrenergics are rarely used in treatment-resistant hypertension:

Endothelium receptor blockers

Bosentan belongs to a new class of drugs and works by blocking endothelin receptors. It is specifically indicated only for the treatment of pulmonary artery hypertension in patients with moderate to severe heart failure.[46]

Choice of initial medication

For mild blood pressure elevation, consensus guidelines call for medically supervised lifestyle changes and observation before recommending initiation of drug therapy. However, according to the American Hypertension Association, evidence of sustained damage to the body may be present even prior to observed elevation of blood pressure. Therefore, the use of hypertensive medications may be started in individuals with apparent normal blood pressures but who show evidence of hypertension-related nephropathy, proteinuria, atherosclerotic vascular disease, as well as other evidence of hypertension-related organ damage.

If lifestyle changes are ineffective, then drug therapy is initiated, often requiring more than one agent to effectively lower hypertension.Which type of many medications should be used initially for hypertension has been the subject of several large studies and various national guidelines. Considerations include factors such as age, race, and other medical conditions. In the United States, JNC8 (2014) recommends any drug from one of the four following classes to be a good choice as either initial therapy or as an add-on treatment: thiazide-type diuretics, calcium channel blockers, ACE inhibitors, or angiotensin II receptor antagonists.

The first large study to show a mortality benefit from antihypertensive treatment was the VA-NHLBI study, which found that chlorthalidone was effective.[47] The largest study, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002, concluded that chlorthalidone (a thiazide-like diuretic) was as effective as lisinopril (an angiotensin converting enzyme inhibitor) or amlodipine (a calcium channel blocker).[48] (ALLHAT showed that doxazosin, an alpha-adrenergic receptor blocker, had a higher incidence of heart failure events, and the doxazosin arm of the study was stopped.)

A subsequent smaller study (ANBP2) did not show the slight advantages in thiazide diuretic outcomes observed in the ALLHAT study, and actually showed slightly better outcomes for ACE-inhibitors in older white male patients.[49]

Thiazide diuretics are effective, recommended as the best first-line drug for hypertension,[50] and are much more affordable than other therapies, yet they are not prescribed as often as some newer drugs. Chlorthalidone is the thiazide drug that is most strongly supported by the evidence as providing a mortality benefit; in the ALLHAT study, a chlorthalidone dose of 12.5 mg was used, with titration up to 25 mg for those subjects who did not achieve blood pressure control at 12.5 mg. Chlorthalidone has repeatedly been found to have a stronger effect on lowering blood pressure than hydrochlorothiazide, and hydrochlorothiazide and chlorthalidone have a similar risk of hypokalemia and other adverse effects at the usual doses prescribed in routine clinical practice.[51] Patients with an exaggerated hypokalemic response to a low dose of a thiazide diuretic should be suspected to have hyperaldosteronism, a common cause of secondary hypertension.[52]

Other medications have a role in treating hypertension. Adverse effects of thiazide diuretics include hypercholesterolemia, and impaired glucose tolerance with increased risk of developing diabetes mellitus type 2. The thiazide diuretics also deplete circulating potassium unless combined with a potassium-sparing diuretic or supplemental potassium. Some authors have challenged thiazides as first line treatment.[53] [54] [55] However, as the Merck Manual of Geriatrics notes, "thiazide-type diuretics are especially safe and effective in the elderly."[56]

Current UK guidelines suggest starting patients over the age of 55 years and all those of African/Afrocaribbean ethnicity firstly on calcium channel blockers or thiazide diuretics, whilst younger patients of other ethnic groups should be started on ACE-inhibitors. Subsequently, if dual therapy is required to use ACE-inhibitor in combination with either a calcium channel blocker or a (thiazide) diuretic. Triple therapy is then of all three groups and should the need arise then to add in a fourth agent, to consider either a further diuretic (e.g. spironolactone or furosemide), an alpha-blocker or a beta-blocker.[57] Prior to the demotion of beta-blockers as first line agents, the UK sequence of combination therapy used the first letter of the drug classes and was known as the "ABCD rule".[57] [58]

Patient factors

The choice between the drugs is to a large degree determined by the characteristics of the patient being prescribed for, the drugs' side effects, and cost. Most drugs have other uses; sometimes the presence of other symptoms can warrant the use of one particular antihypertensive. Examples include:

The JNC8 guidelines indicate reasons to choose one drug over the others for certain individual patients.

Antihypertensive Medication during the First Trimester of Pregnancy

Hypertensive disorders during pregnancy constitute a significant risk factor for maternal and fetal outcomes, necessitating antihypertensive treatment. However, current data concerning the safety of in utero exposure to antihypertensive medication are controversial. While some studies recommend the administration of certain agents, others underline the possible adverse effects on fetal development. In general, a-methyldopa, β-blockers and calcium channel blockers are the first or second treatment line for hypertension during pregnancy. However, ACEIs, ARBs and diuretics are mostly contraindicated, as the potential risk outweighs the benefits of their administration. Additionally, several drugs should be avoided, due to the lack of data regarding their safety.[67] Women are often concerned about the safety of antihypertensives and as a result, many do not take their treatment as prescribed. Shared decision-making aids have been shown to reduce women's uncertainty about taking antihypertensives and increase the number of women taking them as prescribed.[68] [69]

History

History of Thiazides

Chlorothiazide was discovered in 1957, but the first known instance of an effective antihypertensive treatment was in 1947 using primaquine, an antimalarial.[70]

History of Calcium Channel Blockers

In 1883, Ringer discovered the involvement of calcium for cellular activity on isolated heart.[71] Later in 1901, Stiles reported the same activity in muscle contraction. In the early 1940s, Kamada (from Japan) and Heilbrunn (from the United States) noted how calcium was involved with muscle contractions. In 1964, calcium channel blockers were discovered in Godfraind’s laboratory through the screening of coronary dilators, which showed how calcium was blocked from entering artery cells, resulting in vasorelaxation.

Research

Blood pressure vaccines

Vaccinations are being trialed and may become a treatment option for high blood pressure in the future. CYT006-AngQb was only moderately successful in studies, but similar vaccines are being investigated.[72]

Anti-hypertensive drugs in older people

The latest evidence does not have evidence of an effect due to discontinuing vs continuing medications used for treating elevated blood pressure or prevention of heart disease in older adults on all-case mortality and incidence of heart attack.[73] The findings are based on low quality evidence suggesting it may be safe to stop anti-hypertensive medications. However, older adults should not stop any of their medications without talking to a healthcare professional.

Notes and References

  1. Law M, Wald N, Morris J . Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy . Health Technology Assessment . 7 . 31 . 1–94 . 2003 . 14604498 . 10.3310/hta7310 . free .
  2. Drug treatment of elevated blood pressure . Nelson M . Australian Prescriber . 33 . 108–112 . August 11, 2010 . https://web.archive.org/web/20100826074015/http://www.australianprescriber.com/magazine/33/4/108/12 . 26 August 2010 . dead .
  3. Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H . PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998 . The Medical Journal of Australia . 174 . 11 . 565–8 . June 2001 . 11453328 . 10.5694/j.1326-5377.2001.tb143436.x . 204078909 .
  4. Wright JM, Musini VM, Gill R . First-line drugs for hypertension . The Cochrane Database of Systematic Reviews . 2018 . CD001841 . April 2018 . 4 . 29667175 . 10.1002/14651858.CD001841.pub3 . Wright JM . 6513559 .
  5. Web site: Hypertension: Management of hypertension in adults in primary care | Guidance | NICE . 28 June 2006 . 2012-01-09 . live . https://web.archive.org/web/20120107063630/http://www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.pdf . 2012-01-07 ., p19
  6. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL . Thiazide diuretics, potassium, and the development of diabetes: a quantitative review . Hypertension . 48 . 2 . 219–24 . August 2006 . 16801488 . 10.1161/01.HYP.0000231552.10054.aa . free .
  7. Wang TJ, Ausiello JC, Stafford RS . Trends in antihypertensive drug advertising, 1985-1996 . Circulation . 99 . 15 . 2055–7 . April 1999 . 10209012 . 10.1161/01.CIR.99.15.2055 . free .
  8. Heran BS, Chen JM, Wang JJ, Wright JM . Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension . The Cochrane Database of Systematic Reviews . 11 . CD008167 . November 2012 . 23152254 . 10.1002/14651858.CD008167.pub3 . Cochrane Hypertension Group .
  9. Elliott WJ, Ram CV . Calcium channel blockers . Journal of Clinical Hypertension . 13 . 9 . 687–689 . September 2011 . 21896151 . 8108866 . 10.1111/j.1751-7176.2011.00513.x .
  10. Book: Calcium Channel Blockers . 2012 . http://www.ncbi.nlm.nih.gov/books/NBK548577/ . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury . 2023-12-22 . Bethesda (MD) . National Institute of Diabetes and Digestive and Kidney Diseases . 31643892.
  11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Narva AS, Ortiz E . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) . JAMA . 311 . 5 . 507–20 . February 2014 . 24352797 . 10.1001/jama.2013.284427 . free .
  12. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression . Kidney International . 65 . 6 . 1991–2002 . June 2004 . 15149313 . 10.1111/j.1523-1755.2004.00620.x . free .
  13. Book: Spiller HA . ACE Inhibitors . January 2005 . Encyclopedia of Toxicology . 9–11 . Second . Wexler P . https://www.sciencedirect.com/science/article/pii/B0123694000000065 . 2024-03-13 . New York . Elsevier . 10.1016/b0-12-369400-0/00006-5 . 978-0-12-369400-3.
  14. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial . JAMA . 288 . 19 . 2421–31 . November 2002 . 12435255 . 10.1001/jama.288.19.2421 . free .
  15. Barry R. Davis . Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT . Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial . Hypertension . 48 . 3 . 374–84 . September 2006 . 16864749 . 10.1161/01.HYP.0000231662.77359.de . free .
  16. Borghi C, Soldati M, Bragagni A, Cicero AF . Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients . Expert Opinion on Drug Safety . 19 . 12 . 1577–1583 . December 2020 . 33047990 . 10.1080/14740338.2020.1836151 . 222320206 .
  17. Web site: High blood pressure (hypertension) - Uses for ACE inhibitors. Mayo Clinic. 2016-07-27. live. https://web.archive.org/web/20160801120145/http://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480?pg=2. 2016-08-01. Page updated: June 29, 2016
  18. Barreras A, Gurk-Turner C . Angiotensin II receptor blockers . Proceedings . 16 . 1 . 123–126 . January 2003 . 16278727 . 1200815 . 10.1080/08998280.2003.11927893 .
  19. Verma S, Strauss M . Angiotensin receptor blockers and myocardial infarction . BMJ . 329 . 7477 . 1248–9 . November 2004 . 15564232 . 534428 . 10.1136/bmj.329.7477.1248 .
  20. Strauss MH, Hall AS . Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox . Circulation . 114 . 8 . 838–54 . August 2006 . 16923768 . 10.1161/CIRCULATIONAHA.105.594986 . free .
  21. Tsuyuki RT, McDonald MA . Angiotensin receptor blockers do not increase risk of myocardial infarction . Circulation . 114 . 8 . 855–60 . August 2006 . 16923769 . 10.1161/CIRCULATIONAHA.105.594978 . free .
  22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial . Lancet . 363 . 9426 . 2022–31 . June 2004 . 15207952 . 10.1016/S0140-6736(04)16451-9 . 19111421 . 11392/462725 . free .
  23. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial . Lancet . 362 . 9386 . 772–6 . September 2003 . 13678870 . 10.1016/S0140-6736(03)14284-5 . 5650345 .
  24. Levy BI . How to explain the differences between renin angiotensin system modulators . American Journal of Hypertension . 18 . 9 Pt 2 . 134S–141S . September 2005 . 16125050 . 10.1016/j.amjhyper.2005.05.005 . free .
  25. Lévy BI . Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system . Circulation . 109 . 1 . 8–13 . January 2004 . 14707017 . 10.1161/01.CIR.0000096609.73772.C5 . free .
  26. Reudelhuber TL . The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous . Hypertension . 46 . 6 . 1261–2 . December 2005 . 16286568 . 10.1161/01.HYP.0000193498.07087.83 . free .
  27. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . The New England Journal of Medicine . 325 . 5 . 293–302 . August 1991 . 2057034 . 10.1056/nejm199108013250501 . free .
  28. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C . 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America . Circulation . 134 . 13 . e282-93 . September 2016 . 27208050 . 10.1161/CIR.0000000000000435 . free .
  29. Li EC, Heran BS, Wright JM . Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension . The Cochrane Database of Systematic Reviews . 2014 . 8 . CD009096 . August 2014 . 25148386 . 6486121 . 10.1002/14651858.CD009096.pub2 .
  30. Book: Nachawati D, Patel JB . Alpha-Blockers . 2023 . StatPearls . http://www.ncbi.nlm.nih.gov/books/NBK556066/ . 2024-01-21 . Treasure Island (FL) . StatPearls Publishing . 32310526 .
  31. Lindholm LH, Carlberg B, Samuelsson O . Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis . Lancet . 366 . 9496 . 1545–53 . 29 Oct – 4 Nov 2005 . 16257341 . 10.1016/S0140-6736(05)67573-3 . 34364430 .
  32. Carlberg B, Samuelsson O, Lindholm LH . Atenolol in hypertension: is it a wise choice? . Lancet . 364 . 9446 . 1684–9 . 6–12 Nov 2004 . 15530629 . 10.1016/S0140-6736(04)17355-8 . 23759357 .
  33. Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL . Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis . BMJ . 347 . f6008 . October 2013 . 24157497 . 3807847 . 10.1136/bmj.f6008 .
  34. Freemantle N, Cleland J, Young P, Mason J, Harrison J . beta Blockade after myocardial infarction: systematic review and meta regression analysis . BMJ . 318 . 7200 . 1730–7 . June 1999 . 10381708 . 31101 . 10.1136/bmj.318.7200.1730 .
  35. Web site: Hypertension: management of hypertension in adults in primary care . PDF . . 2006-09-30 . dead . https://web.archive.org/web/20070216204848/http://www.nice.org.uk/download.aspx?o=CG034quickrefguide . 2007-02-16 .
  36. Web site: Ladva S . NICE and BHS launch updated hypertension guideline . https://web.archive.org/web/20070929210400/http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=567178 . dead . 2007-09-29 . 2006-06-28 . . 2006-09-30 .
  37. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . Hypertension . 42 . 3 . 239–46 . September 2003 . 12925554 . 10.1161/01.HYP.0000086521.95630.5A . free .
  38. Book: Hariri L, Patel JB . Vasodilators . 2024 . StatPearls . http://www.ncbi.nlm.nih.gov/books/NBK554423/ . 2024-03-16 . Treasure Island (FL) . StatPearls Publishing . 32119310 .
  39. Book: Brunton L, Parker K, Blumenthal D, Buxton I . Goodman & Gilman's Manual of Pharmacology and Therapeutics . 2007 . . New York . 978-0-07-144343-2 . 544–60 . Therapy of hypertension.
  40. Varon J, Marik PE . The diagnosis and management of hypertensive crises . Chest . 118 . 1 . 214–27 . July 2000 . 10893382 . 10.1378/chest.118.1.214.
  41. Web site: Mehta A . Direct Renin Inhibitors as Antihypertensive Drugs. 6 February 2014. January 1, 2011. live. https://web.archive.org/web/20140221232314/http://pharmaxchange.info/press/2011/01/direct-renin-inhibitors-as-antihypertensive-drugs/. 21 February 2014.
  42. Craft J . Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure . Proceedings . 17 . 2 . 217–220 . April 2004 . 16200104 . 1200656 . 10.1080/08998280.2004.11927973 .
  43. Book: Patibandla S, Heaton J, Kyaw H . Spironolactone . 2024 . StatPearls . http://www.ncbi.nlm.nih.gov/books/NBK554421/ . 2024-03-16 . Treasure Island (FL) . StatPearls Publishing . 32119308 .
  44. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report . JAMA . 289 . 19 . 2560–72 . May 2003 . 12748199 . 10.1001/jama.289.19.2560 .
  45. Giovannitti JA, Thoms SM, Crawford JJ . Alpha-2 adrenergic receptor agonists: a review of current clinical applications . Anesthesia Progress . 62 . 1 . 31–39 . 2015 . 25849473 . 4389556 . 10.2344/0003-3006-62.1.31 .
  46. Valerio CJ, Coghlan JG . Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient . Vascular Health and Risk Management . 5 . 607–619 . August 2009 . 19688101 . 2725793 . 10.2147/VHRM.S4713 . free .
  47. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. . 360921 . 1978 . Neurath Jr HM, Goldman AI, Lavin MA, Schnaper HW, Fitz AE, Frohlich ED, Steele B, Richman HG . Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension . Annals of the New York Academy of Sciences . 304 . 267–292 . 10.1111/j.1749-6632.1978.tb25604.x . 40939559 .
  48. Furberg CD, Wright Jr JT, Davis BR, Cutler JA, Alderman M, Black H, etal . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) . JAMA . 288 . 23 . 2981–97 . December 2002 . 12479763 . 10.1001/jama.288.23.2981 . The Allhat Officers And Coordinators For The Allhat Collaborative Research Group . free .
  49. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ . A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly . The New England Journal of Medicine . 348 . 7 . 583–92 . February 2003 . 12584366 . 10.1056/NEJMoa021716 . 2440/4230 . free .
  50. Whelton PK, Williams B . The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: More Similar Than Different . JAMA . 320 . 17 . 1749–1750 . November 2018 . 30398611 . 10.1001/jama.2018.16755 . 53207044 .
  51. Web site: Watson K . 18 May 2016 . Which Thiazide-Type Diuretic Should be First-Line in Patients with Hypertension? . University of Maryland School of Pharmacy .
  52. Web site: Oiseth S, Jones L, Maza E. Hyperaldosteronism. The Lecturio Medical Concept Library . 25 July 2021.
  53. Lewis PJ, Kohner EM, Petrie A, Dollery CT . Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment . Lancet . 1 . 7959 . 564–6 . March 1976 . 55840 . 10.1016/S0140-6736(76)90359-7 . 20976708 .
  54. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT . Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up . Lancet . 2 . 8311 . 1293–5 . December 1982 . 6128594 . 10.1016/S0140-6736(82)91506-9 . 43027989 .
  55. Messerli FH, Williams B, Ritz E . Essential hypertension . Lancet . 370 . 9587 . 591–603 . August 2007 . 17707755 . 10.1016/S0140-6736(07)61299-9 . 26414121 .
  56. Book: Merck Manual of Geriatrics . Section 11. Cardiovascular Disorders – Chapter 85. Hypertension . http://www.merck.com/mkgr/mmg/sec11/ch85/ch85a.jsp . July 2005 . live . https://web.archive.org/web/20090123203540/http://www.merck.com/mkgr/mmg/sec11/ch85/ch85a.jsp . 2009-01-23 .
  57. Web site: CG34 Hypertension – quick reference guide . . 28 June 2006 . 2009-03-04 . https://web.archive.org/web/20090313072133/http://www.nice.org.uk/nicemedia/pdf/cg034quickrefguide.pdf . 13 March 2009 . dead .
  58. Williams B . Treatment of hypertension in the UK: simple as ABCD? . Journal of the Royal Society of Medicine . 96 . 11 . 521–2 . November 2003 . 14594956 . 539621 . 10.1177/014107680309601101 .
  59. Parekh N, Page A, Ali K, Davies K, Rajkumar C . A practical approach to the pharmacological management of hypertension in older people . Therapeutic Advances in Drug Safety . 8 . 4 . 117–132 . April 2017 . 28439398 . 5394506 . 10.1177/2042098616682721 .
  60. Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC . Immunologic adverse reactions of β-blockers and the skin . Experimental and Therapeutic Medicine . 18 . 2 . 955–959 . August 2019 . 31384329 . 10.3892/etm.2019.7504 . 145847997 . free . 6639944 .
  61. Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C . Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel . Internal Medicine Journal . 46 . 10 . 1189–1197 . October 2016 . 27527376 . 5129475 . 10.1111/imj.13215 .
  62. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M . Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout . Journal of Hypertension . 19 . 10 . 1855–1860 . October 2001 . 11593107 . 10.1097/00004872-200110000-00021 . 20842819 .
  63. Worcester EM, Coe FL: Clinical practice. Calcium kidney stones" N Engl J Med 2010;363(10) 954-963. Worcester EM, Coe FL . Clinical practice. Calcium kidney stones . The New England Journal of Medicine . 363 . 10 . 954–63 . September 2010 . 20818905 . 3192488 . 10.1056/NEJMcp1001011 .
  64. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report . JAMA . 289 . 19 . 2560–72 . May 2003 . 12748199 . 10.1001/jama.289.19.2560 . 2013-02-17 . live . https://web.archive.org/web/20130216133645/http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf . 2013-02-16 .
  65. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S . Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention . Circulation . 115 . 21 . 2761–88 . May 2007 . 17502569 . 10.1161/circulationaha.107.183885 . free .
  66. Pietropaoli D, Del Pinto R, Ferri C, Wright JT, Giannoni M, Ortu E, Monaco A . Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults . Hypertension . 72 . 6 . 1365–1373 . December 2018 . 30540406 . 10.1161/HYPERTENSIONAHA.118.11528 . free .
  67. Papadopoulou Z, Tsialiou TM, Styanidou FE, Kavvadas D, Papamitsou T . In Utero Exposure to Antihypertensive Medication during the First Trimester: Is the Risk Worth Taking? . Acta Medica Academica . 50 . 3 . 372–381 . December 2021 . 35164513 . 10.5644/ama2006-124.356 . 246826268 . free .
  68. 15 February 2023 . Decision aid helps pregnant women with high blood pressure . NIHR Evidence. 10.3310/nihrevidence_56796 . 257843687 .
  69. Whybrow R, Sandall J, Girling J, Brown H, Seed PT, Green M, Findlay S, Webster L, Chappell LC . Implementation of a novel shared decision-making intervention in women with chronic hypertension in pregnancy: multiple-site multiple-method investigation . Pregnancy Hypertension . 30 . 137–144 . December 2022 . 36194966 . 10.1016/j.preghy.2022.09.007 . 252414448 . free .
  70. Book: Freis ED . Historical Development of Antihypertensive Treatment . Hyperlension: Pathophysiology, Diagnosis, and Management. . 2741–5 . Second . Laragh JM, Brenner BM . Raven Press, Ltd. . New York . 1995 . https://profiles.nlm.nih.gov/ps/access/XFBBGL.pdf . https://web.archive.org/web/20170222175707/https://profiles.nlm.nih.gov/ps/access/XFBBGL.pdf . 2017-02-22 .
  71. Godfraind T . Discovery and Development of Calcium Channel Blockers . Frontiers in Pharmacology . 8 . 286 . 2017-05-29 . 28611661 . 5447095 . 10.3389/fphar.2017.00286 . free .
  72. Brown MJ . Success and failure of vaccines against renin-angiotensin system components . Nature Reviews. Cardiology . 6 . 10 . 639–47 . October 2009 . 19707182 . 10.1038/nrcardio.2009.156 . 15949 .
  73. Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, Hopper I, Hilmer SN, Gnjidic D . Withdrawal of antihypertensive drugs in older people . The Cochrane Database of Systematic Reviews . 2020 . CD012572 . June 2020 . 6 . 32519776 . 7387859 . 10.1002/14651858.cd012572.pub2 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Antihypertensive drug".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.